miR-486 is essential for muscle function and suppresses a dystrophic transcriptome.

The mRNA Innovators Award offers matching funds to design and validate a therapeutic of interest using Eclipsebio's design models and characterization methods.

Discover how closed-loop RNA development pairs design and sequencing to accelerate better therapeutics.

Originally posted on Business Wire SAN DIEGO, January 26, 2026 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA […]

As RNA therapeutics and regulatory requirements advance, validation methods for IVT RNA integrity are advancing as well.